Decentralized Clinical Trial Models Regulation

Introduction

Decentralized Clinical Trials (DCTs) are clinical research models in which some or most trial activities take place outside traditional clinical trial sites, such as hospitals and research institutions. These trials use digital technologies, remote monitoring, telemedicine, mobile applications, wearable devices, and home-based healthcare services to conduct research activities.

Decentralized clinical trials allow participants to take part in research from their homes or nearby healthcare facilities. They can improve patient convenience, reduce travel requirements, and increase participation among individuals living in remote areas.

However, these models create important legal and regulatory challenges involving informed consent, patient safety, data privacy, electronic records, medical supervision, drug delivery, and accountability. Therefore, appropriate regulatory frameworks are necessary to ensure that decentralized trials maintain the same scientific and ethical standards as conventional clinical trials.

Meaning And Types Of Decentralized Clinical Trials

A decentralized clinical trial distributes research activities between traditional clinical sites and participants' homes or other remote locations.

There are three common models:

1. Fully Decentralized Clinical Trials

Most trial activities occur outside traditional research facilities. Participants may complete assessments, receive remote consultations, and use digital monitoring devices.

2. Hybrid Clinical Trials

Some activities take place at hospitals or research centres, while other activities are conducted remotely. For example, participants may visit a hospital for initial screening but complete follow-up assessments through telemedicine.

3. Site-Less Clinical Trials

These trials rely heavily on digital platforms, remote investigators, mobile healthcare professionals, and electronic data collection systems rather than conventional research sites.

Legal And Regulatory Framework In India

1. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019, provide India's principal regulatory framework for clinical trials involving new drugs.

The rules establish requirements concerning:

Permission from the Central Licensing Authority.

Registration and approval of ethics committees.

Informed consent of participants.

Compensation for clinical trial-related injury or death.

Medical management of trial participants.

Reporting of serious adverse events.

Maintenance of clinical trial records.

These requirements apply to decentralised trials as well. Conducting trial activities remotely does not remove the sponsor's or investigator's regulatory responsibilities.

2. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act provides the statutory foundation for regulating drugs and clinical research in India.

Clinical trial sponsors must comply with applicable statutory requirements and obtain necessary regulatory permissions before conducting regulated clinical trials.

3. Digital Personal Data Protection Act, 2023

Decentralized trials generate significant quantities of digital personal data through mobile applications, wearable devices, telemedicine platforms, and electronic patient records.

The DPDP Act establishes requirements concerning lawful processing, security safeguards, and individual rights. Its application depends on the nature of the information and the commencement of the relevant provisions.

4. ICMR National Ethical Guidelines, 2017

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants establish important principles concerning informed consent, participant safety, confidentiality, scientific validity, and ethics committee supervision.

These guidelines are relevant to decentralised biomedical research involving human participants.

International Regulatory Frameworks

The United States FDA issued guidance titled Conducting Clinical Trials With Decentralized Elements in September 2024.

The guidance addresses remote trial activities, telehealth visits, electronic informed consent, investigational product delivery, remote data collection, and responsibilities of sponsors and investigators.

The European Union's Clinical Trials Regulation (EU) No. 536/2014 provides a framework for clinical trial authorisation, participant protection, and trial supervision.

ICH Good Clinical Practice guidelines, particularly ICH E6(R3), also provide internationally relevant standards for trial quality, participant protection, and reliable clinical data.

Major Regulatory Requirements For Decentralized Clinical Trials

1. Electronic Informed Consent

Participants should receive understandable information about trial objectives, procedures, potential risks, data collection, and their rights. Electronic consent systems should provide appropriate identity verification and documentation.

2. Remote Patient Monitoring

Wearable devices and mobile applications may collect information about heart rate, sleep, movement, blood pressure, and other health indicators. These systems should be appropriately validated for their intended use.

3. Patient Safety And Medical Supervision

Sponsors and investigators must establish procedures for identifying adverse events, providing medical assistance, and referring participants to suitable healthcare facilities.

4. Data Protection And Cybersecurity

Remote trials may involve sensitive health and genetic information. Organisations should implement encryption, access controls, secure authentication, audit trails, and appropriate data-retention policies.

5. Investigational Product Delivery

Where trial medicines are delivered to participants' homes, sponsors must maintain appropriate controls concerning storage, transportation, dispensing, accountability, and product quality.

6. Regulatory Documentation

Trial protocols should clearly identify which activities are performed remotely, which require physical visits, and how trial data will be collected, verified, and preserved.

Relevant Case Laws

Direct judicial decisions specifically regulating decentralized clinical trial models remain limited. However, established clinical research and privacy decisions provide important legal principles.

1. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court of India examined the requirements of informed consent in medical treatment.

The Court emphasised that valid consent requires adequate information about the proposed medical procedure.

Relevance: Decentralized clinical trials must ensure that electronic consent procedures provide participants with sufficient information about research activities, risks, and available alternatives.

2. Common Cause v. Union of India (2018)

The Supreme Court examined the constitutional and legal principles governing patient autonomy and end-of-life medical decisions.

The judgment recognised the importance of individual autonomy in healthcare decisions.

Relevance: Decentralized clinical trial participants must be able to make informed decisions about research participation and exercise their applicable rights without inappropriate pressure.

3. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21 of the Constitution.

Relevance: Remote clinical trials collect sensitive medical information through digital platforms and connected devices. Trial sponsors must establish appropriate safeguards against unnecessary collection, unauthorised access, and disclosure.

4. Jacob Mathew v. State of Punjab (2005)

The Supreme Court examined the legal principles governing criminal liability for medical negligence.

Relevance: Medical professionals involved in remote clinical trial activities must exercise appropriate professional care. Remote monitoring should not eliminate the responsibility to respond properly to serious medical concerns.

These decisions provide related principles concerning consent, autonomy, privacy, and professional responsibility rather than directly establishing DCT-specific regulations.

Challenges In Regulating Decentralized Clinical Trials

Decentralized trials create several practical and legal challenges:

Unequal access to smartphones, internet services, and digital healthcare.

Difficulty verifying participant identity during remote assessments.

Technical errors in wearable devices and monitoring systems.

Delayed identification of serious adverse events.

Uncertainty concerning medical supervision across geographical boundaries.

Cybersecurity risks involving electronic patient records.

Difficulties maintaining consistent clinical trial procedures.

Regulatory authorities must ensure that digital convenience does not weaken participant protection or scientific reliability.

Conclusion

Decentralized clinical trial models represent an important development in modern biotechnology and pharmaceutical research. They improve accessibility and flexibility by using telemedicine, wearable devices, remote monitoring, and electronic consent systems. However, they must comply with established clinical trial requirements concerning informed consent, participant safety, data protection, and scientific reliability. India's New Drugs and Clinical Trials Rules, 2019, ICMR ethical guidelines, and international GCP standards provide important regulatory foundations. Effective oversight is necessary to ensure that decentralized trials remain ethical, transparent, scientifically valid, and legally accountable.